Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing
March 22 2018 - 7:00AM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader
of life science research and clinical diagnostic products, today
announced that it had received an expected notice from the New York
Stock Exchange (the “NYSE”) stating that the Company is not in
compliance with the NYSE's continued listing requirements under the
timely filing criteria established in Section 802.01E of the NYSE
Listed Company Manual due to the Company’s delay in filing its
Annual Report on Form 10-K for the fiscal year ended December 31,
2017 (the "2017 Form 10-K").
As previously disclosed, the reason for the delay is the
additional time needed by Bio-Rad's independent registered public
accounting firm to complete its audit of the Company’s 2017
financial statements including its assessment of the effectiveness
of the Company’s internal control over financial reporting related
to the Company’s conversion in April 2017 to a new ERP system and
business structure for a substantial portion of its European
operations. Bio-Rad intends to file its 2017 Form 10-K as promptly
as possible after its independent registered public accounting firm
completes its audit.
In accordance with NYSE rules, Bio-Rad has contacted the NYSE to
discuss the status of the late filing and is issuing this required
press release. The NYSE informed Bio-Rad that, under NYSE rules,
Bio-Rad will have six months from the Form 10-K due date to file
the 2017 Form 10-K with the SEC. Bio-Rad can regain compliance with
the NYSE listing standards at any time prior to that date by filing
its 2017 Form 10-K.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global
leader in developing, manufacturing, and marketing a broad range of
innovative products and solutions for the life science research and
clinical diagnostic markets. With a focus on quality and customer
service for over 65 years, our products advance the discovery
process and improve healthcare. Our customers are university and
research institutions, hospitals, public health and commercial
laboratories, biotechnology, pharmaceutical, as well as applied
research laboratories that include food safety and environmental
quality testing. Founded in 1952, Bio-Rad is based in Hercules,
California, and has a global network of operations with more than
8,000 employees worldwide. Bio-Rad had revenues exceeding $2.1
billion in 2017. For more information, please visit
www.bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding the anticipated
timing of the filing of the Company’s 2017 Form 10-K. We have based
these statements on the information now known to us. Although we
believe that the assumptions and expectations reflected in these
statements are reasonable, the timing of completion of the audit
process and the filing of the 2017 Form 10-K in order to come into
compliance with the NYSE’s requirements for continued listing is
subject to known and unknown risks and uncertainties and could vary
materially from our current expectations. The Company cautions you
not to place undue reliance on forward-looking statements, which
reflect an analysis only and speak only as of the date hereof.
Bio-Rad Laboratories, Inc. disclaims any obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180322005325/en/
Bio-Rad Laboratories, Inc.Tina Cuccia, 510-724-7000Corporate
Communicationstina_cuccia@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2023 to Apr 2024